Information and calculation tools by Rachid Asen. Not investment advice or research.

Disclaimer. Information tool. Compiles data published by NSE and BSE and calculations from the exchanges' published ESM and ASM criteria. Prices are end-of-day, not live: updated each evening after trading ends. Ethical business criteria are matched by AI, which can make mistakes; this is a criteria match, not a certification, fatwa, rating or advice. Check the company's filings. Not investment advice, research or a recommendation to buy, sell or hold any security; not SEBI-registered as an Investment Adviser or Research Analyst. Calculated dates are the earliest a security could become eligible; inclusion, stage changes and exit are decided solely by the exchanges. ESM, ASM and GSM shortlisting are surveillance measures and not an adverse action against the company. Data may be delayed or inaccurate; verify with the exchange.

AlphaSurveillanceby Rachid AsenNotebookDiscussionConnect AISign in
Market closedIST

Shree Ganesh Remedies Limited

SGRL (NSE) · SGRL (BSE 540737) · ISIN INE414Y01015 · Pharmaceuticals · Est. 1995 · listed 2026 · website

Not on any surveillance list

In Q2 FY27 (quarter to 30 September 2026, consolidated), revenue was ₹23.29 cr and profit after tax ₹1.63 cr. Revenue was 23.2% lower than in Q2 FY26.

Quarterly results

Quarterly results, ₹ crore (as filed)
QuarterRevenueProfit after taxEPS (₹)Filed
Q2 FY27 consolidated₹23.29 cr₹1.63 cr1.2731 Oct 2026
Q1 FY27 consolidated₹14.36 cr₹1.12 cr0.8712 Aug 2026
Q4 FY26 consolidated₹33.2 cr₹6.27 cr4.8815 May 2026
Q3 FY26 consolidated₹21.11 cr₹3.09 cr2.4123 Jan 2026
Q2 FY26 consolidated₹30.32 cr₹4.96 cr3.867 Nov 2025

Balance sheet

Balance sheet, ₹ crore (as filed)
As ofTotal equityBorrowingsTotal assets
31 Mar 2026 standalone₹163.02 cr₹30.67 cr₹207.74 cr
30 Sep 2025 standalone₹153.57 cr₹37.39 cr₹204.15 cr
31 Mar 2025 standalone₹145.19 cr₹38.25 cr₹191.98 cr

Shareholding

Shareholding pattern, Sep 2026
PromoterFIIDIIPublic
72.84%0.00%0.99%27.16%

Latest filings

Other companies in Pharmaceuticals

Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 31 October 2026.

Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.